Scarica l'app Stockscreener
7.10
4.05%
-0.30
Dopo l'orario di chiusura:
7.12
0.02
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.40
Aprire:
$7.4
Volume 24 ore:
8.50M
Relative Volume:
0.68
Capitalizzazione di mercato:
$7.44B
Reddito:
$140.98M
Utile/perdita netta:
$-854.60M
Rapporto P/E:
-8.3138
EPS:
-0.854
Flusso di cassa netto:
$-299.31M
1 W Prestazione:
-7.55%
1M Prestazione:
-8.97%
6M Prestazione:
+10.08%
1 anno Prestazione:
+135.88%
Intervallo 1D:
$7.0637
$7.451
Intervallo di 1 settimana:
$7.0637
$8.14
Portata 52W:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.10 | 7.44B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
Immunitybio Inc (IBRX) Institutional Confidence - TradingKey
Immunitybio Inc (IBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Immunitybio Inc (IBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunitybio Inc (IBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Connect - ACCESS Newswire
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Immunitybio Inc (IBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
ImmunityBio: Revisiting My Bearish Call After A 250% Rise (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound - TechStock²
ImmunityBio (IBRX) Could Be 41% Below Fair Value After Anktiva Optimism - Sahm
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy (NASDAQ:IBRX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio (IBRX) Could Be 41% Undervalued On Anktiva Optimism - Yahoo Finance
ImmunityBio: Intriguing Progress, If Not (Yet) CommerciallyStill A Hold (NASDAQ:IBRX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio - The National Law Review
Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform? - Sahm
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - The National Law Review
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst - TradingView
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk - Sahm
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst - Stocktwits
ImmunityBio Stock Short Interest Falls to 33.94% - Quiver Quantitative
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth - Stocktwits
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares - StocksToTrade
ImmunityBio : IBRX - 24/7 Wall St.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - AOL.com
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - AOL.com
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits
Form 4 Immunitybio Inc For: 6 July By Investing.com - Investing.com Nigeria
ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing - Moomoo
ImmunityBio: A Long-Term Bull Case Worth Watching - Seeking Alpha
ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing - marketscreener.com
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):